C
Cimeio Therapeutics
Developing Shielded-Cell & Drug Pairs to increase cure rates for patients with hematologic malignancies, genetic and autoimmune diseases
About Cimeio Therapeutics
Cimeio is a biotechnology startup that operates in the field of immunotherapy. The company's primary focus is on the development of gene editing tools to enhance the effectiveness of immunotherapy treatments. They have developed a unique technology that allows them to edit a cell surface receptor to prevent antibody binding, while still keeping the receptor fully functional. This process, known as epitope editing, has the potential to shield any cell surface receptor, broadening the application of their technology.
Read full description
Cimeio's technology is particularly useful in the field of hematopoietic stem cells (HSCs) or other types of cells. By inserting novel protein variants into these cells, they can maintain their function while making them resistant to depletion by the paired immunotherapy. This shielding technology has proven to be effective in protecting cells from depletion mediated by antibodies, T-cell engagers, ADCs, and CAR-T cells.
The company's business model revolves around the development and commercialization of this gene editing technology. Their primary clients are likely to be healthcare providers and institutions that are involved in the treatment of diseases that require immunotherapy. By offering a solution that can enhance the effectiveness of these treatments, Cimeio is positioned to generate revenue through the licensing of their technology or through partnerships with healthcare providers.
In terms of market, Cimeio operates in the rapidly growing field of gene editing and immunotherapy. This market is driven by the increasing prevalence of diseases that require innovative treatment approaches, such as cancer and autoimmune diseases.
At a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Cambridge, United States
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 33.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Cardiology and cardiovascular, Immune System, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based, Swiss DT Biotech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Apr 2022 | $50M | $200M | Versant Ventures | ↗ |
| SPINOUTOther financing | Jan 2020 | $0 | — | University of Basel | — |
Growth signals
Latest recorded traffic for Cimeio Therapeutics is 1.3K monthly website visits, down 43.5% over the last three months. Cimeio Therapeutics's team declined 5.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Other known investors1 additional known investor
University of Basel
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cimeio Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cimeio Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.